# Gene Delivery Core

> **NIH NIH P01** · UNIVERSITY OF SOUTH ALABAMA · 2020 · $296,891

## Abstract

CORE SUMMARY
Core C is Gene Delivery Scientific Core whose goal is to provide Program Investigators with complete in vitro
and in vivo gene delivery solutions to facilitate completion of their specific aims. To accomplish this goal, the
Core C will channel its activities into three principal areas: a) providing services; b) developing and acquiring
new technologies, and c) building synergy with Projects and other Cores.
Service component: The Core C will serve a resource for all genetic manipulation needs of Projects and
Cores of this Program. Specifically, the Core C will a) achieve economy of scale and quality assurance
through centralized generation of recombinant DNA, viral constructs, and genetically modified microorganisms
by highly trained personnel; b) provide technical expertise, consultation and training in PCR, RT-PCR, qPCR,
DNA sequencing, gene delivery to prokaryotic and eukaryotic cells, constitutive and regulated gene silencing;
c) execute gene targeting and CRISPR/Cas and TALEN-mediated gene editing in cultured cells for the needs
of PPG projects; d) provide PPG Projects with enabling technologies for the production of genetically modified
laboratory animals, such as Bacterial Artificial Chromosome (BAC) modification, generation CRISPR/Cas
constructs for genome editing and genotyping of genetically altered animals; e) provide PPG investigators with
recombinant protein expression and purification expertise; f) Core C will provide training, experience and
expertise in the field of mitochondrial biology, including generation of cells depleted of mitochondrial DNA and
assays of bioenergetic status using Seahorse XF-24 Extracellular Flux Analyzer.
Academic component: Throughout previous cycles of funding Gene Delivery Core responded to changing
needs of the Projects by either acquiring new technologies or developing its own. This is exemplified by a
spectrum of custom retro- and -lentiviral vectors developed by the Core C, development of a system for
doxycycline-regulated gene expression, development of a system for regulated gene knockdown, by the
development of the gene expression system with a two-tier regulation, etc. In the course of the proposed
competitive renewal, Core C will fully implement, validate, and make available to a broad scientific community
a system for endothelial segment-restricted gene expression. In addition, we plan to establish a system for
point mutations knocking-in in endothelial cells.
Synergy with Projects and Scientific Cores: The Core C is a convergence point for all Projects and Cores
regarding genetic manipulation of pro- and eukaryotic organisms. The Core C also builds synergy with other
Scientific Cores through, e.g. procurement of endothelial cell lines from Core B, modifying these cell lines for
the expression of fluorescent reporters/sensors for the needs of Core D, and supplying these modified cell
lines to Core D for the use and to Core B for distribution to scientific community.

## Key facts

- **NIH application ID:** 9962986
- **Project number:** 5P01HL066299-18
- **Recipient organization:** UNIVERSITY OF SOUTH ALABAMA
- **Principal Investigator:** Mikhail F. Alexeyev
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $296,891
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9962986

## Citation

> US National Institutes of Health, RePORTER application 9962986, Gene Delivery Core (5P01HL066299-18). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9962986. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*